Clindamycin phosphate
Based on 6 publication(s) in Google Scholar
Clindamycin phosphate (Clindamycin 2-phosphate) is a broad-spectrum bacteriostatic lincosamide antibiotic. Clindamycin phosphate is the proagent of Clindamycin (HY-B1455) with no antimicrobial activity in vitro but can be rapidly converted in vivo to the active parent agent, Clindamycin, by phosphatase ester hydrolysis. Clindamycin phosphate can be used for researching acne and bacterial vaginosis. Clindamycin phosphate has no cytotoxicity. Combined with platelet rich fibrin (PRF), PRF-Clindamycin phosphate enhances antimicrobial properties.
For research use only. We do not sell to patients.
- Purity : 99.46%
- CAS No.: 24729-96-2
- Formula: C18H34ClN2O8PS
- Molecular Weight:504.96
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Clindamycin phosphate
MoreAll Antibiotic Isoforms
MoreAll Parasite Isoforms
More
Biological Activity
Description
IC50 & Target
In Vitro
Clindamycin phosphate (10 mg/ml; 24,48 h) shows no significant cytotoxicity in 3T3 mouse fibroblasts[4].
Clindamycin phosphate has MIC values ranging from 125-250 μg/mL for the four Gram-positive bacteria (S. aureus; S. epidermidis; S. aureus; S. epidermidis) and 52.1-62.5 μg/mL for PRF _ CLP[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:3T3 mouse fibroblasts
-
Concentration:10 mg/mL PRF_Clindamycin phosphat:0.01-1 mg/mL
-
Incubation Time:24, 48 h
-
Result:Showed no significant cytotoxicity. At 24 and 48 hours, both Clindamycin phosphat and PRF_Clindamycin phosphat samples maintained cell viability above 70%. PRF_Clindamycin phosphat did not show significant differences in cell viability between different dilutions .
Chemical Information
-
CAS No. 24729-96-2
-
Appearance Solid
-
Molecular Weight 504.96
-
Formula C18H34ClN2O8PS
-
Color White to off-white
-
SMILES
CCC[C@H]1CN(C)[C@H](C(N[C@@]([H])([C@@]2([H])O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]2O)[C@@H](Cl)C)=O)C1
-
Synonyms
Clindamycin 2-phosphate; U-28508
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
EBioMedicine
A novel inhibitor of monooxygenase reversed the activity of tetracyclines against tet(X3)/tet(X4)-positive bacteria. [Abstract]2022 Apr;78:103943. PMID: 35306337 -
Tissue Cell
EZH1-DNMT1 axis inhibits the expression of TFPI2 to promote osteogenic differentiation of periosteum-derived stem cells and accelerate fracture repair. [Abstract]2025 Apr:93:102759. PMID: 39892329 -
-
bioRxiv
Exposure to Antibiotics Modifies the Immune Profiles of Bacterial Extracellular Vesicles from Common Vaginal Anaerobes. [Abstract]2026 May 22:2026.05.21.726874. PMID: 42239425 -
-
Solvent & Solubility
In Vitro:
H2O : 100 mg/mL (198.04 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (99.02 mM); Clear solution; Need ultrasonic
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (397 KB)
- English - EN (397 KB)
- Français - FR (397 KB)
- Deutsch - DE (397 KB)
- Norwegian - NO (397 KB)
- Español - ES (397 KB)
- Swedish - SV (397 KB)
- Italian - IT (397 KB)
- Korean - KR (397 KB)
- Portuguese - PT (397 KB)
-
Handling Instructions (2659 KB)
References
[1]. Li H, et al. Clindamycin hydrochloride and clindamycin phosphate: two drugs or one? A retrospective analysis of a spontaneous reporting system. Eur J Clin Pharmacol. 2017 Feb;73(2):251-253. [Content Brief]
[2]. Hayashi N, et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed-dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: A multicenter, randomized, investigator-blind, parallel-group study. J Dermatol. 2018 Aug;45(8):951-962. [Content Brief]
[4]. Egle K, et al.Injectable Platelet-Rich Fibrin as a Drug Carrier Increases the Antibacterial Susceptibility of Antibiotic-Clindamycin Phosphate. Int J Mol Sci. 2022 Jul 3;23(13):7407 [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 1.9804 mL | 9.9018 mL | 19.8035 mL | 49.5089 mL |
| 5 mM | 0.3961 mL | 1.9804 mL | 3.9607 mL | 9.9018 mL | |
| 10 mM | 0.1980 mL | 0.9902 mL | 1.9804 mL | 4.9509 mL | |
| 15 mM | 0.1320 mL | 0.6601 mL | 1.3202 mL | 3.3006 mL | |
| 20 mM | 0.0990 mL | 0.4951 mL | 0.9902 mL | 2.4754 mL | |
| 25 mM | 0.0792 mL | 0.3961 mL | 0.7921 mL | 1.9804 mL | |
| 30 mM | 0.0660 mL | 0.3301 mL | 0.6601 mL | 1.6503 mL | |
| 40 mM | 0.0495 mL | 0.2475 mL | 0.4951 mL | 1.2377 mL | |
| 50 mM | 0.0396 mL | 0.1980 mL | 0.3961 mL | 0.9902 mL | |
| 60 mM | 0.0330 mL | 0.1650 mL | 0.3301 mL | 0.8251 mL | |
| 80 mM | 0.0248 mL | 0.1238 mL | 0.2475 mL | 0.6189 mL | |
| 100 mM | 0.0198 mL | 0.0990 mL | 0.1980 mL | 0.4951 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.